Document:

THE GEORGE WASHINGTON
UNIVERSITY

 

Patent License Agreement

 

This
Patent License Agreement (this "Agreement") is between The George Washington University, a congressionally chartered
non-profit corporation ("University") located in the District of Columbia, and Protea Biosciences, Inc., a Delaware
corporation (“Company”). Agreement is being signed on November 20, 2012 (“the Execution Date”).This
Agreement will become effective as of November 28, 2012 (the Effective Date”).University and Company may each be
referred to herein individually as "Party" and collectively as the "Parties".

 

 

 

BACKGROUND

 

University
owns certain intellectual property developed by Dr. Akos Vertes of the University's Columbian College of Arts and Sciences relating
to; 1. Laser Desorption/Ionization and Peptide Sequencing on Laser-Induced Silicon Microcolumn Arrays (Matrix) (LISMA, University
Tech Id. 06-00xc Vertes), and 2. Nanophotonic Production, Modulation and Switching of Ions by Silicon Microcolumn Arrays (Nanophotonic
Arrays, University Tech Id. 09-00xd Vertes) (collectively "GW Inventions"). University also owns certain letters patent
and/or applications for letters patent relating to the intellectual property. Additionally University is a joint owner with UT
Battelle, LLC, under the authority of its Prime Contract (No. DE-AC05-00OR22725) ("UTB") with the U.S. Department of
Energy, of certain intellectual property developed by Dr. Akos Vertes, and Dr. Scott Retterer of UTB relating to Laser Desorption/Ionization
from Nanopost Arrays for Mass Spectrometry (NAPA, University Tech Id. 09-00xb Vertes) ("GW/UTB Invention"). UTB has
agreed to designate University as being responsible for licensing UTB's interest in the GW/UTB Invention. Company desires to obtain
an exclusive license under the patent rights to exploit the GW Inventions and GW/UTB Invention. University has determined that
the exploitation of the intellectual property by Company is in the best interest of University and is consistent with its educational
and research missions and goals.

 

In
consideration of the mutual obligations contained in this Agreement, and intending to be legally bound, the Parties agree as follows:

 

1
LICENSE

 

1.1
License Grant. University grants to Company an exclusive, world-wide license (the "License") to make, have
made, use, import, offer for sale and sell Licensed Products in the Field of Use during the Term (as such terms may be defined
in Sections 1.2 and 6.1). The License includes the right to sublicense as permitted by this Agreement. No other rights or licenses
are granted by University.

 

1.2 Related Definitions.
The term "Licensed Products" means products and services that are made, made for, used, imported, offered for
sale or sold by Company or its Affiliates or sublicensees and that would (i) in the absence of the License, infringe (or, in the
case of pending patent applications, upon issuance, would infringe) at least one claim of the Patent Rights or (ii) use a process
or machine covered by a claim of Patent Rights, whether the claim is issued or pending. The term "Patent Rights"
means all of University's patent rights represented by or issuing from: (a) the United States patents and patent applications
listed in Exhibit A; (b) any continuation, continuation-in-part, divisional and re issue applications of (a); and (c) any foreign
counterparts and extensions of (a) or (b). The term "Affiliate" means a legal entity that is controlling, controlled
by or under common control with Company and that has executed either this Agreement or a written Joinder Agreement agreeing to
be bound by all of the terms and conditions of this Agreement. For purposes of his Section 1.2, the word "control"
means (x) the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of a legal
entity, (y) the right to receive fifty percent (50%) or more of the profits or earnings of a legal entity, or (z) the right to
determine the policy decisions of a legal entity. The term "Field of Use" means only products and services for
(a) investigative and exploratory research and (b) human and veterinary diagnostic use.

 

 

    	1

    	 

    

 

1.3
Reservation of Rights by University. University reserves the right to use, and to permit other non-commercial entities to
use, the Patent Rights for educational and research purposes.

 

1.4
U.S. Government Rights. The Parties acknowledge that the United States government retains rights in intellectual property
funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States
government rights, including, but not limited to, any applicable requirement that products, which result from such intellectual
property and are sold in the United States, must be substantially manufactured in the United States. Furthermore, the License is
subject to, and will in no way restrict, the march-in rights of the United States government pursuant to 35 USC § 203.

 

1.5
Sublicense Conditions. The Company's right to sublicense granted by University under the License is subject to each of the
following conditions:

 

(a)
In each sublicense agreement, Company will prohibit the sublicensee from further sublicensing and require the sublicensee to comply
with the terms and conditions of this Agreement.

 

(b)
Within thirty (30) days after Company enters into a sublicense agreement, Company will deliver to University a complete and accurate
copy of the entire sublicense agreement written in the English language. University's receipt of the sublicense agreement, however,
will constitute neither an approval of the sublicense nor a waiver of any right of University or obligation of Company under this
Agreement.

 

(c)In the
event that Company causes or experiences a Trigger Event (as defined in Section 6.4), all payments due to Company from its
Affiliates or sublicensees under the sublicense agreement will, upon notice from University to such Affiliate or sublicensee,
become payable directly to University for the account of Company. Upon receipt of any such funds, University will remit to
Company the amount by which such payments exceed the amounts owed by Company to University.

 

(d) Company
will terminate any sublicense agreement within ten (10) business days in the event that the sublicensee causes or experiences
any of the following: (i) if sublicensee (1) becomes insolvent or bankrupt, (2) is adjudicated insolvent or bankrupt, (3)
admits in writing its inability to pay its debts, (4) suffers the appointment of a custodian, receiver or trustee for it or
its property and, if appointed without its consent, not discharged within thirty (30) days, (5) makes an assignment for the
benefit of creditors, or (6) suffers proceedings being instituted against it under any law related to bankruptcy, insolvency,
liquidation or the reorganization, readjustment or release of debtors and, if contested by it, not dismissed or stayed within
thirty (30) days; (ii) the institution or commencement by sublicensee of any proceeding under any law related to bankruptcy,
insolvency, liquidation or the reorganization, readjustment or release of debtors; (iii) the entering of any order for relief
relating to any of the proceedings described in Section 1.5(d)(i) or (ii) above; (iv) the calling by sublicensee of a meeting
of its creditors with a view to arranging a composition or adjustment of its debts in connection with any of the events
described in Section 1.5(d)(i), (ii) or (iii) above; (v) the act or failure to act by sublicensee indicating its consent to,
approval of or acquiescence in any of the proceedings described in Section 1.5(d)(i)-(iv) above; (vi) the commencement by
sublicensee of any action against University, including an action for declaratory judgment, to declare or render invalid or
unenforceable the Patent Rights, or any claim thereof; and (vii) breaches the sublicense agreement and does not cure the
breach within forth-five (45) days after written notice of the breach. If the termination of a sublicense agreement is stayed
by any court, Company will not be obligated to seek termination of the stay.

 

    	2

    	 

    

 

(e)
Company's execution of a sublicense agreement will not relieve Company of any of its obligations under this Agreement. Company
is primarily liable to University for any act or omission of an Affiliate or sublicensee of Company that would be a breach of this
Agreement if performed or omitted by Company, and Company will be deemed to be in breach of this Agreement as a result of such
act or omission if, subject to the provisions of Section 1.5(d), Company fails to terminate such sublicense agreement following
any applicable cure period or fails to take reasonable steps to cure any such act or omission.

 

1.6
No License by Implication. Nothing in this Agreement confers by estoppel implication or otherwise, any license or rights
under any University patent other than the Patent Rights, regardless whether such patents are dominant or subordinate to the Patent
Rights.

  

2
DILIGENCE

 

2.1
Development Plan. Company will deliver to University, no later than October 31, 2012, a copy of an initial development plan for
the Patent Rights (the "Development Plan"). The purpose of the Development Plan is (a) to demonstrate Company's
capability to bring the Patent Rights to commercialization, (b) to project the timeline for completing the necessary tasks, and
(c) to measure Company's progress against the projections. Thereafter, Company will deliver to University an annual updated Development
Plan no later than December 1 of each year during the Term. The Development Plan will include, at a minimum, the information listed
in Exhibit B.

 

2.2
Company's Efforts. Company will use commercially reasonable efforts to develop, commercialize, market and sell Licensed
Products in a manner consistent with the Development Plan.

 

2.3
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the diligence events by the applicable
completion date listed in the table below for the first Licensed Product.

 

	DILIGENCE EVENT	
        COMPLETION

        DATE

	Delivery to University  of a completed Development Plan in a form acceptable to University 	June 15, 2013
	First Commercial sale of the Licensed Product   	July 1, 2015

 

2.4 Diligence
Resources. Until the first commercial sale of the first Licensed Product, Company will expend resources in the development
and commercialization of the Licensed Products of amounts not less than the diligence minimums specified in the table below in
each 12-month period following the Effective Date. The Company's expenditures for development and commercialization of the Licensed
Products include, but are not limited to, with respect to the Licensed Products, all of Company's research and development expenditures
and overhead, any Sponsored Research Agreement between University and Company, any sponsored research agreement between Company
and a third party, sponsorship of graduate students, any regulatory expenses, and documented external consulting payments. If
Company's total expenditures for development and commercialization of Licensed Products in any 12-month period do not meet or
exceed the applicable diligence minimum, then Company will pay to University the amount of the shortfall. Company will make any
payments of the shortfall to University with the next annual updated Development Plan due to University under Section 2.1. If
Company's total expenditures for development and commercialization of Licensed Products in any 12-month period exceed the applicable
diligence minimum, the excess amount will be cumulated and credited toward the applicable diligence minimums for subsequent years.

 

 

    	3

    	 

    

 

	ANNIVERSARY:	First	Second	Third and thereafter until the first commercial sale of the first Licensed Product
	LICENSE DILIGENCE RESOURCES:	$0	$12,500	$20,000

 

FEES
AND ROYALTIES

 

3.1
License Initiation Fee. In partial consideration of the License, Company will pay to University within thirty (30) days
from the Effective Date a non-refundable, non-creditable license initiation fee of Twenty-Five Thousand ($25,000) United States
dollars.

 

3.2
Milestone Payments. In partial consideration of the License, Company will pay to University the applicable milestone payment
listed in the table below after achievement of each milestone event for each Licensed Product. Company will provide University
with written notice within thirty (30) days after achieving each milestone.

 

	MILESTONE	PAYMENT
	First Sale of Licensed Product 	$30,000

 

 

For
clarity, each time a milestone is achieved with respect to a Licensed Product, then any other milestone payments with respect
to earlier milestones that have not yet been paid will be due and payable together with the milestone payment for the milestone
that is actually achieved. For additional clarity, milestones are due and payable on Licensed Products and on products that, upon
FDA approval, would become Licensed Products.

 

3.3
Earned Royalties. In partial consideration of the License, Company will pay to University a royalty of on Net Sales of Licensed
Products and Combination Product during the Quarter as follows.

 

		(a)	Seven (7) percent of Net Sales of Licensed Products
and five (5) percent of Net Sales of Combination Products for combined cumulative Net Sales of Licensed Products and Combination
Products up to fifty million US dollars;

 

		(b)	When documented combined cumulative Net Sales of Licensed
Products and Combination Products have exceeded fifty million US dollars, six (6) percent of Net Sales of Licensed Products and
Four (4) percent of Net Sales of Combination Products.

 

    	4

    	 

    

 

 

Royalty shall be due on the sale
of a Licensed Product only once. For avoidance of doubt, for a Licensed Product that is covered by the claims of the Patent Rights
licensed under this Agreement but also qualifies to be licensed product under Other License, Company shall only pay royalties for
the Licensed Product pursuant to this Agreement.

 

3.4 Related Definitions.
The term "Sale" means any bona fide transaction for which consideration is received or expected by Company or
its Affiliate or sublicensee for the sale, use, lease, transfer or other disposition of a Licensed Product to a third party. A
Sale is deemed completed at the time that Company or its Affiliate or sublicensee invoices, ships or receives payment for a Licensed
Product, whichever occurs first. The term "Quarter" means each three-month period beginning on January 1,
April 1, July 1 and October 1. The term "Net Sales" means the consideration received or expected from,
or the fair market value attributable to, each Sale, less Qualifying Costs that are directly attributable to a Sale, specifically
identified on an invoice or other documentation and actually borne by Company or its Affiliates or sublicensees. For purposes
of determining Net Sales, the words ''fair market value" mean the cash consideration that Company or its Affiliates
or sublicensees would realize from an unrelated buyer in an arm’s length sale of an identical item sold in the same quantity
and at the time and place of the transaction. The term "Qualifying Costs" means: (a) customary discounts in the
trade for quantity purchased or for wholesalers and distributors; (b) credits or refunds for claims or returns that do
not exceed the original invoice amount; (c) prepaid outbound transportation expenses and transportation insurance premiums; and
(d) sales and use taxes and other fees imposed by and indefeasibly paid to a governmental agency. "Combination Product"
means a Licensed Product in the Field of Use that infringes at least one issued and unexpired claim of a third party patent
to which Company has acquired a royalty-bearing license with an annual royalty rate greater than four (4) percent of Net Sales
and under which the Company is currently making royalty payments to the licensor. Royalties payable to University on Combination
Product shall be based on total Net Sales of such Combination Product, regardless of the number of components or their relative
value.

 

3.5 Minimum Royalties. In partial consideration of the License, Company will pay to University the amount, if any
that the applicable minimum royalty listed in the table below exceeds Company's actual earned royalties under Section 3.3 for
each Quarter after the first Sale of a Licensed Product.

 

	
        QUARTER:

         
	
        First 4 Quarters

         
	
        Next 4 Quarters

         

         
	
        Next 4 Quarters

         

         
	
        All Quarters thereafter

         

	MINIMUM:	$1,500	$2,500	$3,500	$6,000

 

3.6
Sublicense Fees. In partial consideration of the License, Company will pay to University a sublicense fee of fifty percent
(50%) of the sum of all payments plus the fair market value of all other consideration of any kind, received by Company from sublicensees
during the Quarter, excluding: (a) royalties paid to Company by a sublicensee based upon Sales or Net Sales by the sublicensee;
(b) equity investments in Company by a sublicensee up to the amount of the fair market value of the equity purchased on the date
of the investment; (c) loan proceeds paid to Company by a sublicensee in an arm’s length, full recourse debt financing to
the extent that such loan is not forgiven; and (d) sponsored research funding paid to Company by a sublicensee in a bona fide transaction
for future research to be performed by Company.

 

3.7
Other License Agreement. Company has licensed certain other patent rights of University under two separate license agreements
made effective on February 22, 2010, as amended from time to time (the "LAESI License") and June 1, 2011 (the "Protein
Microscope License") (both together "Other License").

 

    	5

    	 

    

 

 

4 REPORTS AND PAYMENTS

 

 

4.1
Royalty Reports. Within forty-five (45) days after the end of each Quarter following the first Sale, Company will deliver
to University a report, certified by the chief 3.5
Minimum Royalties. In partial consideration of the License, Company will pay to University the amount, if any that the applicable
minimum royalty listed in the table below exceeds Company's actual earned royalties under Section 3.3 for each Quarter after the
first Sale of a Licensed Product.financial officer of Company, detailing the calculation of all royalties, fees and
other payments due to University for such Quarter. The report will include, at a minimum, the following information for the Quarter,
each listed by product, by country: (a) the number of units of Licensed Products constituting Sales; (b) the gross consideration
invoiced, billed or received for Sales; (c) Qualifying Costs, listed by category of cost; (d) Net Sales; (e) the gross amount of
any payments and other consideration received by Company from sublicensees and the amounts of any deductions permitted by Section
3.6; (f) the royalties, fees and other payments owed to University, listed by category; and (g) the computations for any applicable
currency conversions. Each royalty report will be substantially in the form of the sample report attached as Exhibit C.

 

4.2
Payments3.5
Minimum Royalties. In partial consideration of the License, Company will pay to University the amount, if any that the applicable
minimum royalty listed in the table below exceeds Company's actual earned royalties under Section 3.3 for each Quarter after the
first Sale of a Licensed Product.. Company will pay all royalties, fees and other payments due to University under Sections 3.2, 3.3, 3.5, and 3.6
within forty-five (45) days after the end of the Quarter in which the royalties, fees or other payments accrued.

 

4.3 Records3.5
Minimum Royalties. In partial consideration of the License, Company will pay to University the amount, if any that the
applicable minimum royalty listed in the table below exceeds Company's actual earned royalties under Section 3.3 for each Quarter
after the first Sale of a Licensed Product.. Company will maintain, and will cause its Affiliates and sublicensees to maintain,
complete and accurate books, records and related background information to verify Sales, Net Sales, and all of the royalties,
fees, and other payments due or paid under this Agreement, as well as the various computations reported under Section 4.1. The
records for each Quarter will be maintained for at least five (5) years after submission of the applicable report required under
Section 4.1 or longer as necessary to document the amount of cumulative combined Net Sales of Licensed and Combination Products
as required under section 3.3.

 

4.4
Audit Rights. Upon reasonable prior written notice to Company, Company and its Affiliates and sublicensees will provide
University and its accountants with access to all of the books, records and related background information required by Section
4.3 to conduct a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement.
Access will be made available: (a) during normal business hours; (b) in a manner reasonably designed to facilitate University's
review or audit without unreasonable disruption to Company's business; and (c) no more than once every two (2) consecutive calendar
years during the Term (as defined below) and for a period of five (5) years thereafter. Company will promptly pay to University
the amount of any underpayment determined by the review or audit, plus accrued interest. If the review or audit determines that
Company has underpaid any payment by ten percent (10%) or more, then Company will also promptly pay the costs and expenses of University
and its accountants in connection with the review or audit. In addition, once annual Sales of Licensed Products exceed Five Million
Dollars ($5,000,000), Company will conduct, at least once every two (2) years at its own expense, an independent audit of Sales,
Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement. Promptly after completion of the
audit, Company will provide to University a copy of the report of the independent auditors along with any underpayments and interest
thereon.

 

4.5 Currency.
All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments will be made in United States
dollars. If Company receives payment from a third party in a currency other than United States dollars for which a royalty or fee
is owed under this Agreement, then (a) the payment will be converted into United States dollars at the conversion rate for the
foreign currency as published in the eastern edition of the Wall Street Journal as of the last business day of the Quarter in which
the payment was received by Company, and (b) the conversion computation will be documented by Company in · the applicable
report delivered to University

under Section 4.1.

 

 

    	 

    	 

    

 

4.6Place of
Payment. All payments by Company are payable to "The George Washington University" and will be made to the following
addresses:

 

 

	By Electronic Transfer:	By Check:
	Bank's Name:	PNC Bank, N.A.	The George Washington University
	Bank's Address:  	800 Connecticut Avenue, NW	Office of Technology Transfer
	 	Washington, DC 20052	Office of the Vice President for Research
	ABA#	031000053	2033 K Street, NW, Suite 750
	Account Name:   	GW Deposit Account	Washington, DC 20052
	Account Number:	 5303553334	 
	SWIFT:	PNCCUS33	Attention:·Director

 

4.7
 Interest. All amounts that are not paid by Company when due will accrue interest from the date due until paid at a rate
equal to one and one-half percent (1.5%) per month (or the maximum allowed by law, if less).

 

 

5
CONFIDENTIALITY AND USE OF UNIVERSITY'S NAME

 

5.1
Confidentiality. Except as specifically permitted hereunder, each Party hereby agrees to hold in confidence and not use
on behalf of itself or others all technology, data, samples, technical and economic information (including economic terms hereof),
commercialization, clinical and research strategies, know-how and trade secrets provided by the other Party (the "Disclosing
Party") (collectively the "Confidential Information"), except that the term "Confidential Information"
shall not include:

 

		(a)	information that is or becomes part of the public
domain through no fault of the non Disclosing Party;

 

		(b)	information that is obtained after the Effective Date
by the non-Disclosing Party or one of its Affiliates from any third party which is lawfully in possession of such Confidential
Information and not in violation of any contractual or legal obligation to the Disclosing Party with respect to such Confidential
Information;

 

		(c)	information that is known to the non-Disclosing Party
or one or more of its Affiliates prior to the disclosure by the Disclosing Party, as evidenced by the non-Disclosing Party's written
records; and

 

		(d)	information which has been independently developed
by the non-Disclosing Party without the aid or use of Confidential information as shown by competent written evidence.

 

5.2
Required Disclosure. The non-Disclosing Party may disclose the Disclosing Party's proprietary information to the extent
required to comply with a court or administrative subpoena or a lawful court order provided that the non-Disclosing Party first
uses its best efforts to obtain an order preserving the confidentiality of the information of the Disclosing Party and provided
the non Disclosing Party gives the Disclosing Party timely notice of the contemplated disclosure to give the Disclosing Party an
opportunity to intervene to preserve the confidentiality of the information.

 

    	 

    	 

    

 

 

 

5.3
Patent Exception. Upon prior review of the University, Company may disclose in a patent application or the prosecution thereof,
any Confidential Information necessary to obtain or secure patent protection of the commercialized products or processes.

 

5.4
Use of University's Name. Company and its Affiliates, sublicensees, employees, and agents may not use the name, logo, seal,
trademark, or service mark (including any adaptation of them) of University or any University school, organization, employee, student
or representative, without the prior written consent of University.

 

 

6 TERM AND TERMINATION

 

6.1
Term. This Agreement will commence on Effective Date and terminate upon the expiration or abandonment of the last patent
to expire or become abandoned of the Patent Rights (the "Term").

 

6.2
Early Termination by Company. Company may terminate this Agreement at any time effective upon completion of each of the
following conditions: (a) providing at least sixty (60) days prior written notice to University of such intention to terminate;
(b) ceasing to make, have made, use, import, offer for sale and sell all Licensed Products; (c) terminating all sublicenses and
causing all Affiliates and sublicensees to cease making, having made, using, importing, offering for sale and selling all Licensed
Products; and (d) paying all amounts owed to University under this Agreement and any Sponsored Research Agreement between University
and Company related to the Patent Rights, through the effective date of termination.

 

6.3
Early Termination by University. University may terminate this Agreement if: (a) Company is more than thirty (30) days late
in paying to University any amounts owed under this Agreement and does not pay University in full, including accrued interest,
within ten (10) business days upon demand (a "Payment Default"); (b) other than a Payment Default, Company or its Affiliate
breaches this Agreement and does not cure the breach within forty-five.(45) days after written notice of the breach; (c) Company
fails to timely terminate a sublicense agreement in accordance with Section 1.5(d); or (d) Company or its Affiliate experiences
a Trigger Event.

 

6.4
Trigger Event. The term "Trigger Event" means any of the following: (a) if Company or its Affiliate (i)
becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt,
(iii) admits in writing its inability to pay its debts, (iv) suffers the appointment of a custodian, receiver or trustee for it
or its property and, if appointed without its consent, not discharged within thirty (30) days, (v) makes an assignment for the
benefit of creditors, or (vi) suffers proceedings being instituted against it under any law related to bankruptcy, insolvency,
liquidation or the reorganization, readjustment or release of debtors and, if contested by it, not dismissed or stayed within thirty
(30) days; (b) the institution or commencement by Company or its Affiliate of any proceeding under any law related to bankruptcy,
insolvency, liquidation or the reorganization, readjustment or release of debtors; (c) the entering of any order for relief relating
to any of the proceedings described in Sections 6.4(b) or (c) above; (d) the calling by Company or its Affiliate of a meeting of
its creditors with a view to arranging a composition or adjustment of its debts in connection with any of the events described
in Section 6.4(a), (b) or (c) above; (e) the act or failure to act by Company or its Affiliate indicating its consent to, approval
of or acquiescence in any of the proceedings described in Section 6.4(b) - (e) above; or (f)the commencement by Company of any
action against University, including an action for declaratory judgment, to declare or render invalid or unenforceable the Patent
Rights, or any claim thereof.

 

 

    	 

    	 

    

 

6.5
Effect of Termination. Upon the termination of this Agreement for any reason: (a) the License terminates; (b) Company and
all its Affiliates and sublicensees will cease all making, having made, using, importing, offering for sale and selling all Licensed
Products, except to extent permitted by Section 6.6; (c) Company will pay to University all amounts, including accrued interest,
owed to University under this Agreement and any Sponsored Research Agreement related to the Patent Rights, through the date of
termination, including royalties on Licensed Products invoiced or shipped through the date of termination, whether or not payment
is received prior to termination; (d) Company will, at University's request, return to University all confidential information
of University and "provide to University one complete copy of all data with respect to Licensed Products generated by Company
during the Term that will facilitate the further development of the technology licensed under this Agreement; and (e) in the case
of termination under Section 63, all duties of University and all rights (but not duties) of Company under this Agreement
immediately terminate without further action required by either University or Company.

 

6.6
Inventory & Sell Off. Upon the termination of this Agreement for any reason, Company will cause physical inventories
to be taken immediately of: (a) all completed Licensed Products on hand under the control of Company or its Affiliates or sublicensees;
and (b) such Licensed Products as are in the process of manufacture and any component parts on the date of termination of this
Agreement. Company will deliver promptly to University a copy of the written inventory, certified by an officer of the Company.
Upon termination of this Agreement for any reason, Company will promptly remove, efface or destroy all references to University
from any advertising, labels, web sites or other materials used in the promotion of the business of Company or its Affiliates or
sublicensees, and Company and its Affiliates and sublicensees will not represent in any manner that it has rights in or to the
Patent Rights or the Licensed Products. Upon the termination of this Agreement for any reason other than pursuant to Section 6.3(a)
or (c), Company may sell off its inventory of Licensed Products existing on the date of termination for a period of six (6) months
and pay University royalties on Sales of such inventory within thirty (30) days following the expiration of such six (6) month
period.

 

6.7 Survival.
Company's obligation to pay all amounts that have accrued but have not been paid at the date of termination and all royalties
that accrue· after the· date of termination for the Sale of Company's inventory of Licensed Products existing
on the date of termination as permitted in Section 6.6 above, including accrued interest, owed to University under this Agreement
will survive the termination of this Agreement for any reason. Sections 13.9, 13.10, and 13.11 and Articles 4, 5, 6, 9, 10, and
11 will survive the termination of this Agreement for any reason in accordance with their respective terms.

  

7PATENT
PROSECUTION AND MAINTENANCE

 

7.1
Patent Control. University controls the preparation, prosecution and maintenance of the Patent Rights and the selection
of patent counsel, with input from Company. For the purpose of this article, the terms "maintenance" includes
any interference negotiations, claims, or proceeding, in any forum, brought by University, Company, a third party, or the United
States Patent and Trademark Office (the "USPTO") and, and any requests by University or Company that the USPTO reexamine
or reissue any patent in the Patent Rights.

  

    	 

    	 

    

 

7.2 Payment
and Reimbursement. Company agrees that the University has incurred a total of twenty-six-thousand one-hundred thirty-three
and 68/100 United States Dollars (USD 26,133.68)as historically accrued attorney fees, expenses, official fees and all other charges
accumulated prior to the Effective Date incident to the preparation, filing, prosecution and maintenance of the Patent Rights
(the "Past Patent Expenses"). Within thirty (30) days after the Effective Date, Company will reimburse University for
all historically accrued attorney fees, expenses, official fees and all other charges accumulated prior to the Effective Date
incident to the preparation, filing, prosecution and maintenance of the Patent Rights. Thereafter, Company hereby agrees to reimburse
University for all documented attorneys fees, expenses, official fees and all other charges accumulated on or after the Effective
Date incident to the preparation, filing, prosecution, and maintenance of the Patent Rights, within thirty (30) days after Company's
receipt of invoices for such fees, expenses and. charges. University reserves the right to require the Company to provide a deposit
in advance of incurring out of pocket patent expenses estimated by counsel to exceed $5,000. If Company fails to reimburse patent
expenses under this Paragraph 7.2 then University will be free at its discretion and expense to either abandon such applications
or patents related to such Patent Right or to continue such preparation, prosecution and/or maintenance activities, and to the
extent University has pursued protection of any patent rights associated with such patent action will remain subject to the license
granted under this Agreement. Any abandonment of patents or applications under Patent Rights by the University shall not affect
Company's obligation to pay royalties under this Agreement.

  

8
INFRINGEMENT

 

8.1
Notice. Company and University will notify each other promptly of any infringement of the Patent Rights that may come to
their attention. Company and University will consult each other in a timely manner concerning any appropriate response to the infringement.

 

8.2
Prosecution of Infringement. Company may prosecute any infringement of the Patent Rights at Company's expense, including
defending against any counterclaims or cross claims brought by any party against Company or University, or UTB as applicable, regarding
the Patent Rights and defending against any claim that the Patent or Patent Rights are invalid in the course of any infringement
action or in a declaratory judgment action. University reserves the right to intervene voluntarily and join Company in any such
infringement litigation relating to the GW Inventions or the GW/UTB Invention. Company acknowledges that UTB reserves the right
to intervene voluntarily and join Company in any such infringement litigation relating to the GW/UTB Invention. If University and/or
UTB chooses not to intervene voluntarily, but University and/or UTB is a necessary party to the action brought by Company, then
Company may join University and/or UTB in the infringement litigation. If Company decides not to prosecute any infringement of
the Patent Rights, then University and/or UTB may elect to prosecute such infringement independently of Company in the sole discretion
of the University and/or UTB.

 

8.3
Cooperation. In any litigation under this Article 8, either Party, at the request and sole expense of the other Party, will
cooperate to the fullest extent reasonably possible. This Section 8.3 will not be construed to require either Party to undertake
any activities, including legal discovery, at the request of any third party, except as may be required by lawful process of a
court of competent jurisdiction. If, however, either Party is required to undertake any activity, including legal discovery, as
a right of lawful process of a court of competent jurisdiction, then Company will pay all expenses incurred by Company, by University
and by UTB. ·

 

8.4  Control
of Litigation. Company controls any litigation or potential litigation involving the prosecution of infringement claims regarding
the Patent Rights in which University is not a party, including the selection of counsel, all with input from University. Company
must not settle or compromise any such litigation in a manner that imposes any obligations or restrictions on University or grants
any rights to the Patent Rights, other than any permitted sublicenses, without University’s prior written permission. University
controls any litigation or potential litigation involving the prosecution of infringement claims regarding the Patent Rights in
which University has elected to prosecute the infringement independently of Company or has voluntarily or involuntarily joined
Company in the infringement litigation, including the selection of counsel, all with input from Company. In all instances in which
University is a party, University reserves the right to select its own counsel. If University is involuntarily joined as a party,
University retains the right to select its own counsel, but Company will be responsible for all litigation expenditures as set
forth in Section 8.5.

 

 

    	 

    	 

    

 

8.5
Recoveries from Litigation. If Company prosecutes any infringement claims either without University as a party or with University
involuntarily joined as a party, then Company will reimburse University for University's litigation expenditures, including any
attorneys’ fees, expenses, official fees and other charges incurred by University, even if there are no financial recoveries
from the infringement action. Company will reimburse University within thirty (30) days after receiving each invoice from University.
After reimbursing University for its expenditures, Company will use the financial recoveries from such claims, if any, (a) first,
to reimburse Company for its litigation expenditures; and (b) second, to retain any remainder but to treat the remainder as either
(i) Net Sales for the purpose of determining the royalties due to University under Section 3.6 or (ii) sublicense consideration
for the purpose of determining the sublicense fees due to University under Section 3.9, whichever would result in a larger payment
to University. If Company prosecutes any infringement claims with University joined as a voluntary party, then any financial recoveries
from such claims will be (x) first, shared between Company and University in proportion with their respective shares of the aggregate
litigation expenditures by Company and University; and (y) second, shared equally by Company and University as to any remainder
after Company and University have fully recovered their aggregate litigation expenditures. If University prosecutes any infringement
claims independent of Company, then University will prosecute such infringement at University's expense and will retain any financial
recoveries in their entirety.

 

 

9
DISCLAIMER OF WARRANTIES

 

9.1
Disclaimer. THE PATENT RIGHTS, LICENSED PRODUCTS AND ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON
AN “AS IS” BASIS. UNIVERSITY MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED
TO ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY,
NON-INFRINGEMENT OR TITLE.

 

 

10
LIMITATION OF LIABILITY

 

10.1
Limitation of University's Liability. UNIVERSITY WILL NOT BE LIABLE TO COMPANY, ITS AFFILIATES, SUBLICENSEES, SUCCESSORS
OR ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM ARISING FROM COMPANY'S USE OF THE PATENT RIGHTS, LICENSED PRODUCTS OR
ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT; OR ARISING FROM THE DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED
PRODUCTS. UNIVERSITY WILL NOT BE LIABLE TO COMPANY, ITS AFFILIATES, SUBLICENSEES, SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY FOR
LOST PROFITS, BUSINESS INTERRUPTION, OR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

 

 

    	 

    	 

    

 

 

10.2
Limitation of Company's Liability. COMPANY WILL NOT BE LIABLE TO UNIVERSITY, ITS AFFILIATES, TRUSTEES, OFFICERS, FACULTY,
EMPLOYEES, AGENTS, SUCCESSORS OR ASSIGNS FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

  

11INDEMNIFICATION

 

11.1
Indemnification. Company will defend, indemnify, and hold harmless each Indemnified Party from and against any and all Liabilities
with respect to an Indemnification Event. The term “Indemnified Party” means each of University and its trustees,
officers, faculty, students, employees, contractors, and agents. The term “Liabilities” means all damages, awards,
deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes,
liens, losses, lost profits and expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys,
accountants and other experts) that are incurred by an Indemnified Party or awarded or otherwise required to be paid to third parties
by an Indemnified Party. The term “Indemnification Event” means any Claim against one or more Indemnified Parties
arising out of or resulting from: (a) the development, testing, use, manufacture, promotion, sale or other disposition of any Patent
Rights or Licensed Products by Company, its Affiliates, sublicensees, assignees or vendors or third parties, including, but not
limited to, (i) any product liability or other Claim of any kind related to use by a third party of a Licensed Product, (ii) any
Claim by a third party that the practice of any of the Patent Rights or the design, composition, manufacture, use, sale or other
disposition of any Licensed Product infringes or violates any patent, copyright, trade secret, trademark or other intellectual
property right of such third party, and (iii) any Claim by a third party relating to clinical trials or studies for Licensed Products;
(b) any material breach of this Agreement by Company or its Affiliates or sublicensees; and (c) the enforcement of this Article
11 by any Indemnified Party. The term “Claim” means any charges, complaints, actions, suits, proceedings, hearings,
investigations, claims or demands.

 

11.2
Reimbursement of Costs. Company will pay directly all Liabilities incurred for defense or negotiation of any Claim or will
reimburse University for all documented Liabilities incident to the defense or negotiation of any Claim within thirty (30) days
after Company's receipt of invoices for such fees, expenses and charges.

 

11.3
Control of Litigation. Company controls any litigation or potential litigation involving the defense of any Claim, including
the selection of counsel, with input from University. University reserves the right to protect its interest in defending against
any Claim by selecting its own counsel, with any attorneys' fees and litigation expenses paid for by Company, pursuant to Sections
11.1 and 11.2. Should University voluntarily join any litigation, including defense of any Claim, University shall cover all expenses
related to its legal representation.

 

11.4 Additional
Indemnification. Company represents and warrants that it will not export any technical information (or the direct product
thereof) furnished to Company, either directly or indirectly by the University in the grant of license to the Patent Rights, from
the United States of America, directly or indirectly without first complying with all requirements of the Export Administration
Regulations, including the requirement for obtaining any export license, if applicable. Company will indemnify, defend and hold
harmless Indemnified Parties from liability involving the violation of such export regulations, either directly or indirectly,
by Company. Company further agrees to indemnify and hold harmless Indemnified Parties from and against any and all liabilities,
penalties, fines, forfeitures, claims, demands, causes of action, damages, and costs and expenses (including the costs of defense,
prosecution and/or settlement, including, but not limited to, attorney’s fees), caused by, arising out of or related to,
in whole or in part, Company and/or any Sublicensee’s exercise of rights under this Agreement or any other action or inaction
relating to Licensed Patents, Licensed Products, or Licensed Processes, including, but not limited to, claims or demands of product
liability, personal injury, death, damage to property or violation of any laws or regulations, except for those arising from University’s
gross negligence.

 

 

    	 

    	 

    

 

11.5
Other Provisions. Company will not settle or compromise any Claim giving rise to Liabilities in any manner that imposes any
restrictions or obligations on University or grants any rights to the Patent Rights or the Licensed Products without University's
prior written consent. If Company fails or declines to assume the defense of any Claim within thirty (30) days after notice of
the Claim, or fails to reimburse an Indemnified Party for any Liabilities pursuant to Sections 11.1 and 11.2 within the thirty
(30) day time period set forth in Section 11.2, then University may assume the defense of such Claim for the account and at the
risk of Company, and any Liabilities related to such Claim will be conclusively deemed a liability of Company. The indemnification
rights of the Indemnified Parties under this Article 11 are in addition to all other rights that an Indemnified Party may have
at law, in equity or otherwise.

  

12
INSURANCE

 

12.1
Coverages. Company will procure and maintain insurance policies for the following coverages with respect to personal injury,
bodily injury and property damage arising out of Company's performance under this Agreement: (a) during the Term, comprehensive
general liability, including broad form and contractual liability, in a minimum amount of $2,000,000 combined single limit per
occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving Licensed Products, clinical trials
coverage in a minimum amount of $3,000,000 combined single limit per occurrence and in the aggregate; and (c) prior to the Sale
of the first Licensed Product, product liability coverage, in a minimum amount of $2,000,000 combined single limit per occurrence
and in the aggregate. University may review periodically the adequacy of the minimum amounts of insurance for each coverage required
by this Section 12.1, and University reserves the right to require Company to adjust the limits accordingly. The required minimum
amounts of insurance do not constitute a limitation on Company's liability or indemnification obligations to University under this
Agreement.

 

12.2
Other Requirements. The policies of insurance required by Section 12.1 will be issued by an insurance carrier with an A.M.
Best rating of “A” or better and will name University as an additional insured with respect to Company’s performance
under this Agreement. Company will provide University with insurance certificates evidencing the required coverage within thirty
(30) days after the Effective Date and the commencement of each policy period and any renewal periods. Each certificate will provide
that the insurance carrier will notify University in writing at least thirty (30) days prior to the cancellation or material change
in coverage.

  

13
ADDITIONAL PROVISIONS

 

13.1
Independent Contractors. The parties are independent contractors. Nothing contained in this Agreement is intended to create
an agency, partnership or joint venture between the parties. At no time will either Party make commitments or incur any charges
or expenses for or on behalf of the other Party.

 

13.2 No Discrimination.
Neither University nor Company will discriminate against any employee or applicant for employment because of race, color, sex,
sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status.

 

 

    	 

    	 

    

 

13.3
Compliance with Laws. Company must comply with all prevailing laws, rules and regulations that apply to its activities or
obligations under this Agreement. For example, Company will comply with applicable United States export laws and regulations. The
transfer of certain technical data and commodities may require a license from the applicable agency of the United States government
and/or written assurances by Company that Company will not export data or commodities to certain foreign countries without prior
approval of the agency. University does not represent that no license is required, or that, if required, the license will issue.

 

13.4
Modification, Waiver & Remedies. This Agreement may only be modified by a written amendment that is executed by an authorized
representative of each Party. Any waiver must be express and in writing. No waiver by either Party of a breach by the other Party
will constitute a waiver of any different or succeeding breach. Unless otherwise specified, all remedies are cumulative.

 

13.5 
Assignment & Hypothecation. Company may not assign this Agreement or any part of it, either directly or by merger or
operation of law, without the prior written consent of University. University will not unreasonably withhold or delay its consent,
provided that: (a) at least thirty (30) days before the proposed transaction, Company gives University written notice and such
background information as may be reasonably necessary to enable University to give an informed consent; (b) the assignee agrees
in writing to be legally bound by this Agreement and to deliver to University an updated Development Plan within forty-five (45)
days after the closing of the proposed transaction; and (c) Company provides University with a copy of assignee's undertaking.
Any permitted assignment will not relieve Company of responsibility for performance of any obligation of Company that has accrued
at the time of the assignment. Company will not grant a security interest in the License or this Agreement during the Term. Any
prohibited assignment or security interest will be null and void.

 

13.6
Notices. Any notice or other required communication (each, a “Notice”) must be in writing, addressed
to the Party's respective Notice Address listed on the signature page, and delivered: (a) personally; (b) by certified mail, postage
prepaid, return receipt requested; (c) by recognized overnight courier service, charges prepaid; or (d) by facsimile. A Notice
will be deemed received: if delivered personally, on the date of delivery; if mailed, five (5) days after deposit in the United
States mail; if sent via courier, one (1) business day after deposit with the courier service; or if sent via facsimile, upon receipt
of confirmation of transmission provided that a confirming copy of such Notice is sent by certified mail, postage prepaid, return
receipt requested.

 

13.7
Severability & Reformation. If any provision of this Agreement is held to be invalid or unenforceable by a court of
competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable
provision will be automatically revised to be a valid or enforceable provision that comes as close as permitted by law to the parties'
original intent.

 

13.8
Headings & Counterparts. The headings of the articles and sections included in this Agreement are inserted for convenience
only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in several
counterparts, all of which taken together will constitute the same instrument.

 

13.9 Governing
Law. This Agreement and all amendments, modifications, alterations, or supplements hereto, and the rights of the parties hereunder,
shall be construed under and governed by the laws of the District of Columbia, without regard to principles of conflict of laws
thereof which may require the application of the law of another jurisdiction. Unless otherwise agreed to by the parties, only
courts in District of Columbia shall have jurisdiction to hear and decide any controversy or claim between the parties arising
under or relating to this Agreement.

 

 

    	 

    	 

    

 

13.10
Dispute Resolution. If a dispute arises between the parties concerning any right or duty under this Agreement, then the
parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the parties are unable to resolve the dispute
amicably, then the parties will submit to the exclusive jurisdiction of, and venue in, the local or Federal courts of the District
of Columbia with respect to all disputes arising under this Agreement.

 

13.11
Integration. This Agreement with its Exhibits contain the entire agreement between the parties with respect to the Patent
Rights and the License and supersede all other oral or written representations, statements, or agreements with respect to such
subject matter, including but not limited to the Term Sheet.

 

Each Party has caused this Agreement
to be executed by its duly authorized representative.

 

	THE GEORGE WASHINGTON UNIVERSITY	PROTEA BIOSCIENCES, INC
	 	 
	By: /s/ Leo M. Chalupa	By: /s/ Stephen Turner
	Name: Leo M. Chalupa	Name: Stephen Turner
	Title: Vice President for Research	Title: President
	Date: ________________________	Date: ________________________
	 	 
	Addresses:	 
	 	 
	Office of Technology Transfer	Protea Biosciences, Inc.
	Office of the Vice President for Research	955 Hartman Run Road, Suite 210
	The George Washington University	Morgantown, WV 26507
	2033 K Street, NW, Suite 750	 
	Washington, DC 20052	Attention: President
	 	 
	 	 

 

Attention: Director

Required
copy to:

The
George Washington University

Office
of the Sr. Vice President & General Counsel

2100
Pennsylvania Avenue NW, Suite 250

Washington,
DC 20052

Attention:
General Counsel

 

    	 

    	 

    

 

 EXHIBIT INDEX

 

 

	 	 
	Exhibit A	Patents and Patent Applications in Patent Rights
	 	 
	Exhibit B	Minimum Contents of Development Plan
	 	 
	Exhibit C	Format of Royalty Report
	 	 
	Exhibit D	Payments Due under sections 3.1 and 7.2

 

 

 

    	 

    	 

    

 

Exhibit A

 

 Patent Rights: List of patents
and current pending patent applications

 

 

	GWU Technology Docket Number	
         

         

        Status
	
         

         

        Country
	
         

        Application

        Number
	
         

        Application

        Date
	
         

        Patent

        Number
	
         

         

        Title
	
         

         

        Inventors

	
         

         

        006-000xc-
        Vertes
	
         

         

         

        Expired
	
         

         

         

        USA
	
         

         

         

        60/808,544
	
         

         

         

        05/26/2006
	 	Laser Desorption Ionization and peptide Sequencing on Laser Induced Microcolumn  Arrays	
         

         

        Vertes, Akos; Yong

        Chen

	
         

         

        006-000xc- Vertes
	
         

         

         

        Granted
	
         

         

         

        USA
	
         

         

         

        11/674,671
	
         

         

         

        26/01/2006
	
         

         

         

        8,084,734
	Laser Desorption Ionization and Peptide Sequencing on Laser Induced Silicon Microcolumn Arrays	
         

         

        Vertes, Akos; Yong

        Chen

	
         

         

        009-00xb- Vertes
	
         

         

        Expired
	
         

         

        USA
	
         

         

        61/167,442
	
         

         

        04/07/2009
	 	Tailored Nanopost Arrays (NAPA) for Laser Desorption/Ionization in Mass Spectrometry	
         

        Vertes, Akos; Walker, Bennett;
        Stolee, Jessica; Retterer, Scott; Pickel, Deanna

	
         

         

        009-00xb-
        Vertes
	
         

         

        Pending
	
         

         

        USA
	
         

         

        12/755,769
	
         

         

        4/7/2010
	 	Tailored Nanopost Arrays (NAPA) for Laser Desorption/Ionization in Mass Spectrometry	
         

        Vertes, Akos; Walker, Bennett; Stolee, Jessica;
        Retterer, Scott; Pickel, Deanna

	
         

         

        009-000xd-
        Vertes
	
         

         

         

        Expired
	
         

         

         

        USA
	
         

         

         

        61/145,544
	
         

         

         

        1/17/2009
	
         

         

         

        .
	Nanophotonic Production, Modulation  and Switching of Ions by Silicon Microcolumn Arrays	
         

         

        Vertes, Akos; Walker, Bennett;

	
         

         

        009-000xd-
        Vertes
	
         

         

         

        Granted
	
         

         

         

        USA
	
         

         

         

        12/689,829
	
         

         

         

        1/19/2010
	
         

         

         

        8,110,796
	Nanophotonic Production, Modulation  and Switching of lons by Silicon Microcolumn Arrays	
         

         

        Vertes, Akos; Walker, Bennett;

	
         

         

        009-000xd- Vertes
	
         

         

         

        Pending
	
         

         

         

        USA
	
         

         

         

        13/348,285
	
         

         

         

        1/11/2012
	 	Nanophotonic Production, Modulation  and Switching of lons by Silicon Microcolumn Arrays	
         

         

        Vertes, Akos; Walker,
        Bennett;

 

 

 

    	 

    	 

    

 

Exhibit B

 

 

 

Development Plan
Contents

 

The initial Development
Plan and each update to the Development Plan will include, at a minimum, the following information:

 

		·	The date of the
Development Plan and the reporting period covered by the Development Plan.

		·	Identification
and nature of each active relationship between Company and its Affiliates, sublicensees or subcontractors in the research, development
or commercialization of Licensed Products or Patent Rights

		·	Significant projects
completed during the reporting period by Company or its Affiliates, sublicensees or subcontractors in the research, development
or commercialization of Licensed Products or Patent Rights.

		·	Significant projects
currently being performed by Company or its Affiliates, sublicensees or subcontractors in the research, development or commercialization
of Licensed Products or Patent Rights.

		·	Future projects
expected to be undertaken during the next reporting period by Company or its Affiliates, sublicensees or subcontractors in the
research, development or commercialization of Licensed Products or Patent Rights.

		·	Projected timelines to product launch
of each Licensed Product prior to first Sale.

		·	Projected annual Net Sales for each Licensed
Product after first Sale.

		·	Significant changes
to the current Development Plan since the previous Development Plan and the reasons for the changes.

		·	Significant assumptions
underlying the Development Plan and the future variables that may cause significant changes to the Development Plan.

 

 

 

 

    	 

    	 

    

 

 Exhibit C

 

Form for Royalty Report

  

		Royalty Report
	 	 
	Licensee: Protea Biosciences, Inc.	Agreement LISMA/NAPA/Nanophot
	Inventor(s): Akos vertes, et al.	Patent #(s)  various
	Period Covered:	Prepared B
	From	Date
	To	Approved B
	 	Date

If license
covers several major product lines, please prepare a separate report for each line. Then combine all product lines into a summary
report.

 

	Report Type	o  Single Product Line Report	 
	          	o
     Multiple product  Summary Report  Page ____ of  ____	 
	 	o  Product Line Detail: 	Line	 
	 	 	Trade Name	 
	      	 	Page	 

 

 

Report Currency: o US Dollars o Other
(specify) _(Please request an alternate form)

 

 

    	 

    	 

    

 

 

Exhibit D

 

Invoice of Payments Due Under Sections
3.1 and 7.2

 

 

THE GEORGE WASHINGTON UNIVERSITY

WASHINGTON DC

 

 

 

Receivable

Receivable
details

 

1
Article 3.1 License Initiation Fee, due on Effective Date of License $25,000.00

 

2
Article 7.2 Payment and Reimbursement of Past Patent Expenses incurred prior to the $26,133.68

Effective Date*

 

	Tech ld 009-000xb-Vertes	 	$	6,465.32	 
	Tech ld 006-000xc-Vertes	 	$	8,780.03	 
	Tech ld 009-000xd-Vertes	 	$	10,888.33	 
	Sub Total	 	$	26,133.68	 

  

*This
amount can change depending on the date of execution of the license Agreement

Tax
ID: 53-019654 Balance Due by 27-Sep-12 Total Due: $51,133.68THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE
OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ ACT”), OR ANY STATE SECURITIES
LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.

 

WARRANT AGREEMENT

 

WSA 00157

 

To Purchase Shares of Common Stock of

 

NEURALSTEM, INC.

 

Dated as of March 22, 2013 (the “Effective
Date”)

 

WHEREAS, Neuralstem, Inc., a Delaware corporation, has entered
into a Loan and Security Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology III,
L.P., a Delaware limited partnership, (the “Warrantholder”);

 

WHEREAS, the Company (as defined below) desires to grant to
Warrantholder, in consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right
to purchase shares of Common Stock (as defined below) pursuant to this Warrant Agreement (the “Agreement”);

 

NOW, THEREFORE, in consideration of the Warrantholder executing
and delivering the Loan Agreement and providing the financial accommodations contemplated therein, and in consideration of the
mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows:

 

SECTION 1.          GRANT
OF THE RIGHT TO PURCHASE COMMON STOCK.

 

For value received, the Company hereby grants to the Warrantholder,
and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase,
from the Company, an aggregate number of fully paid and non-assessable shares of the Common Stock equal to the quotient derived
by dividing (a) $700,000 by (b) the Exercise Price (defined below). As used herein, the following terms shall have the following
meanings:

 

“Act” means the Securities Act
of 1933, as amended.

 

“Company” means Neuralstem, Inc.,
a Delaware corporation, and any successor or surviving entity that assumes the obligations of the Company under this Agreement
pursuant to Section 8(a).

 

“Charter” means the Company’s
Articles of Incorporation, Certificate of Incorporation or other constitutional document, as may be amended from time to time.

 

“Common Stock” means the Company’s
common stock, $0.01 par value per share;

 

“Equity Round”
means any non-public offering of equity securities by the Company, that closes between December 22, 2012 and March 22, 2014, in
a transaction or series of related transactions principally for equity financing purposes in which the cash is received by the
Company and/or debt of the Company is cancelled or converted in exchange for equity securities of the Company.

 

“Exercise Price” means the lower
of (A) $1.0789, or (B) the effective price of any Common Stock in an Equity Round, in each case subject to adjustment pursuant
to Section 8.

 

“Merger Event” means any sale,
lease or other transfer of all or substantially all assets of the Company or any merger or consolidation involving the Company
in which the Company is not the surviving entity, or in which the outstanding shares of the Company’s capital stock are otherwise
converted into or exchanged for shares of Common stock, other securities or property of another entity;

 

    	1

    	 

    

 

“Purchase Price” means, with respect
to any exercise of this Agreement, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares
of Common Stock requested to be exercised under this Agreement pursuant to such exercise; and

 

“SEC” means Securities and Exchange
Commission.

 

SECTION 2.       TERM
OF THE AGREEMENT.

 

Except as otherwise provided for herein, the term of this Agreement
and the right to purchase Common Stock as granted herein (the “Warrant) shall commence on the Effective Date and shall be
exercisable for a period ending five (5) years from the Effective Date.

 

SECTION 3.       EXERCISE
OF THE PURCHASE RIGHTS.

 

(a)          Exercise.
The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or from
time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a
notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed
and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms
set forth below, and in no event later than three (3) days thereafter, the Company shall issue to the Warrantholder a certificate
for the number of shares of Common Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto
as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject
to future purchases, if any.

 

The Purchase Price may be paid at the Warrantholder’s
election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Common Stock to be
exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable
hereunder, as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method, the Company
will issue Common Stock in accordance with the following formula:

 

X = Y(A-B)

A

 

	Where:	X =	the number of shares of Common Stock to be issued to the Warrantholder.
	 	 	 
	 	Y =	the number of shares of Common Stock requested to be exercised under this Agreement.
	 	 	 
	 	A =	the fair market value of one (1) share of Common Stock at the time of issuance of such shares of Common Stock.
	 	 	 
	 	B =	the Exercise Price.

 

For purposes of the above calculation, current fair market value
of Common Stock shall mean with respect to each share of Common Stock:

 

(i)          if
the Common Stock is traded on a securities exchange, the fair market value shall be deemed to be the product of (x) the average
of the closing prices over a five (5) day period ending three days before the day the current fair market value of the securities
is being determined and (y) the number of shares of Common Stock into which each share of Common Stock is convertible at the time
of such exercise; or

 

(ii)         if
the Common Stock is traded over-the-counter, the fair market value shall be deemed to be the product of (x) the average of the
closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three days before
the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which
each share of Common Stock is convertible at the time of such exercise;

 

    	2

    	 

    

 

(iii)        if
at any time the Common Stock is not listed on any securities exchange or quoted in the NASDAQ National Market or the over-the-counter
market, the current fair market value of Common Stock shall be the highest price per share which the Company could obtain from
a willing buyer (not a current employee or director) for shares of Common Stock sold by the Company, from authorized but unissued
shares, as determined in good faith by its Board of Directors, unless the Company shall become subject to a Merger Event, in which
case the fair market value of Common Stock shall be deemed to be the per share value received by the holders of the Company’s
Common Stock on a common equivalent basis pursuant to such Merger Event.

 

Upon partial exercise by either cash or Net Issuance, the Company
shall promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and
conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective
Date hereof.

 

(b)          Exercise
Prior to Expiration. To the extent this Agreement is not previously exercised as to all Common Stock subject hereto, and if
the fair market value of one share of the Common Stock is greater than the Exercise Price then in effect, this Agreement shall
be deemed automatically exercised pursuant to Section 3(a) (even if not surrendered) immediately before its expiration. For purposes
of such automatic exercise, the fair market value of one share of the Common Stock upon such expiration shall be determined pursuant
to Section 3(a). To the extent this Agreement or any portion thereof is deemed automatically exercised pursuant to this Section
3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Common Stock, if any, the Warrantholder
is to receive by reason of such automatic exercise.

 

SECTION 4.       RESERVATION
OF SHARES.

 

During the term of this Agreement, the Company will at all times
have authorized and reserved a sufficient number of shares of its Common Stock to provide for the exercise of the rights to purchase
Common Stock as provided for herein.

 

SECTION 5.       NO
FRACTIONAL SHARES OR SCRIP.

 

No fractional shares or scrip representing fractional shares
shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the Company shall make a cash payment
therefor upon the basis of the Exercise Price then in effect.

 

SECTION 6.       NO
RIGHTS AS STOCKHOLDER.

 

This Agreement does not entitle the Warrantholder to any voting
rights or other rights as a stockholder of the Company prior to the exercise of this Agreement.

 

SECTION 7.       WARRANTHOLDER
REGISTRY.

 

The Company shall maintain a registry showing the name and address
of the registered holder of this Agreement. Warrantholder’s initial address, for purposes of such registry, is set forth
below Warrantholder’s signature on this Agreement. Warrantholder may change such address by giving written notice of such
changed address to the Company.

 

SECTION 8.       ADJUSTMENT
RIGHTS.

 

The Exercise Price and the number of shares of Common Stock
purchasable hereunder are subject to adjustment, as follows:

 

    	3

    	 

    

 

(a)          Merger
Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so
that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of Common
stock or other securities or property (collectively, “Reference Property”) that the Warrantholder would have
received in connection with such Merger Event if Warrantholder had exercised this Agreement immediately prior to the Merger Event.
In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors and reasonably
acceptable to the Warrantholder) shall be made in the application of the provisions of this Agreement with respect to the rights
and interests of the Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments
of the Exercise Price and adjustments to ensure that the provisions of this Section 8 shall thereafter be applicable, as nearly
as possible, to the purchase rights under this Agreement in relation to any Reference Property thereafter acquirable upon exercise
of such purchase rights) shall continue to be applicable in their entirety, and to the greatest extent possible. Without limiting
the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the
obligations of this Agreement; provided that if the Reference Property includes shares of stock or other securities and assets
of an entity other than the successor or purchasing company, as the case may be, in such Merger Event, then such other entity shall
assume the obligations under this Agreement and any such assumption shall contain such additional provisions to protect the interests
of the Warrantholder as reasonably necessary by reason of the foregoing (as determined in good faith by the Company’s Board
of Directors and reasonably acceptable to the Warrantholder) . In connection with a Merger Event and upon Warrantholder’s
written election to the Company, the Company shall cause this Warrant Agreement to be exchanged for the consideration that Warrantholder
would have received if Warrantholder had chosen to exercise its right to have shares issued pursuant to the Net Issuance provisions
of this Warrant Agreement without actually exercising such right, acquiring such shares and exchanging such shares for such consideration.
The provisions of this Section 8(a) shall similarly apply to successive Merger Events.

 

(b)          Reclassification
of Shares. Except for Merger Events subject to Section 8(a), and subject to Section 8(f), if the Company at any time shall,
by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which
purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes, this
Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the
result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately
prior to such combination, reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall similarly
apply to successive combination, reclassification, exchange, subdivision or other change.

 

(c)          Subdivision
or Combination of Shares. If the Company at any time shall combine or subdivide its Common Stock, (i) in the case of a subdivision,
the Exercise Price shall be proportionately decreased, or (ii) in the case of a combination, the Exercise Price shall be proportionately
increased.

 

(d)          Stock
Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall:

 

(i)          pay
a dividend with respect to the Common Stock payable in Common Stock, then the Exercise Price shall be adjusted, from and after
the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying
the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be
the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator
of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution; or

 

(ii)         make
any other distribution with respect to Common Stock, except any distribution specifically provided for in any other clause of this
Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon
exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the Common
Stock as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution.

 

    	4

    	 

    

 

(e)          Antidilution
Rights. Additional antidilution rights applicable to the Common Stock purchasable hereunder are as set forth in the Charter
and shall be applicable with respect to the Common Stock issuable hereunder. The Company shall promptly provide the Warrantholder
with any restatement, amendment, modification or waiver of the Charter; provided, that no such amendment, modification or
waiver shall impair or reduce the antidilution rights applicable to the Common Stock as of the date hereof unless such amendment,
modification or waiver affects the rights of Warrantholder with respect to the Common Stock in the same manner as it affects all
other holders of Common Stock. The Company shall provide Warrantholder with prior written notice of any issuance of its stock or
other equity security to occur after the Effective Date of this Agreement, which notice shall include (a) the price at which such
stock or security is to be sold, (b) the number of shares to be issued, and (c) such other information as necessary for Warrantholder
to determine if a dilutive event has occurred. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment
pursuant to this subsection (e), the foregoing subsection (d) and the Charter.

 

(f)          Notice
of Adjustments. If: (i) the Company shall declare any dividend or distribution upon its stock, whether in stock, cash, property
or other securities (assuming Warrantholder consents to a dividend involving cash, property or other securities); (ii) the Company
shall offer for subscription prorata to the holders of its Common Stock or other capital stock any additional shares of stock of
any class or other rights; (iii) there shall be any Merger Event; (iv) the Company shall sell, lease, license or otherwise transfer
all or substantially all of its assets; or (v) there shall be any voluntary dissolution, liquidation or winding up of the Company;
then, in connection with each such event, the Company shall send to the Warrantholder: (A) at least thirty (30) days’ prior
written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend, distribution,
subscription rights (specifying the date on which the holders of Common Stock shall be entitled thereto) or for determining rights
to vote in respect of such Merger Event, dissolution, liquidation or winding up; and (B) in the case of any such Merger Event,
sale, lease, license or other transfer of all or substantially all assets, dissolution, liquidation or winding up, at least thirty
(30) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders
of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such Merger
Event, dissolution, liquidation or winding up).

 

Each such written notice shall set forth, in reasonable detail,
(i) the event requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the
method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and
(D) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall be given by first class
mail, postage prepaid, or by reputable overnight courier with all charges prepaid, addressed to the Warrantholder at the address
for Warrantholder set forth in the registry referred to in Section 7.

 

(g)          Timely
Notice. Failure to timely provide such notice required by subsection (f) above shall entitle Warrantholder to retain the benefit
of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Warrantholder.
For purposes of this subsection (g), and notwithstanding anything to the contrary in Section 12(g), the notice period shall begin
on the date Warrantholder actually receives a written notice containing all the information required to be provided in such subsection
(f). Notwithstanding the foregoing, notice shall be deemed given in the event that the Company discloses such information via a
filing on the SEC’s Edgar website and delivers to Warrantholder an electronic link to such filing information.

 

    	5

    	 

    

 

SECTION 9.       REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE COMPANY.

 

(a)          Reservation
of Common Stock. The Common Stock issuable upon exercise of the Warrantholder’s rights has been duly and validly reserved
and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and
will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Common Stock issuable
pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The Company has
made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates
for shares of Common Stock upon exercise of this Agreement shall be made without charge to the Warrantholder for any issuance tax
in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of
Common Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer
and the issuance and delivery of any certificate in a name other than that of the Warrantholder.

 

(b)          Due
Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company
hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock and the Common Stock into
which it may be converted, have been duly authorized by all necessary corporate action on the part of the Company. This Agreement:
(1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation
or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture,
mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid
and binding agreement of the Company, enforceable in accordance with its terms.

 

(c)          Consents
and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect
of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance
by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act
and any filing required by applicable state securities law, which filings will be effective by the time required thereby.

 

(d)          Issued
Securities. All issued and outstanding shares of Common Stock, Common Stock or any other securities of the Company have been
duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Common Stock and
any other securities were issued in full compliance with all federal and state securities laws. In addition,
as of the date immediately preceding the date of this Agreement:

 

(i)          The
authorized capital of the Company consists of (A) __150,000,000________ shares of Common Stock, of which __68,447,314________ shares
are issued and outstanding, and (B) _____7,000,000_____ shares of Preferred Stock, of which ___0_______ shares are issued and outstanding
and are convertible into _______n/a___ shares of Common Stock at $____n/a__ per share.

 

(ii)         The
Company has reserved ___38,564,368_______ shares of Common Stock for issuance under its Stock Option Plan(s), under which ___16,787,287_______
options are outstanding. Additionally, the Company has reserved ___20,211,667____ shares of Common Stock for issuance pursuant
to outstanding warrants, restricted stock units and other convertible securities. There are no other options, warrants, conversion
privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s
capital stock or other securities of the Company. The Company has no outstanding loans to any employee, officer or director of
the Company, and the Company agrees not to enter into any such loan or otherwise guarantee the payment of any loan made to an employee,
officer or director by a third party.

 

(iii)        In
accordance with the Company’s Charter, no stockholder of the Company has preemptive rights to purchase new issuances of the
Company’s capital stock.

 

(e)          [Intentionally
omitted.]

 

    	6

    	 

    

 

(f)          Other
Commitments to Register Securities. Except as previously disclosed to Warrantholder or as disclosed in the Company’s
public filings with the SEC, the Company is not, pursuant to the terms of any other agreement currently in existence, under any
obligation to register under the Act any of its presently outstanding securities or any of its securities which may hereafter be
issued.

 

(g)          Exempt
Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of this Warrant
and the Common Stock upon exercise of this Agreement will each constitute a transaction exempt from (i) the registration requirements
of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state
securities laws.

 

(h)          Compliance
with Rule 144. If the Warrantholder proposes to sell Common Stock issuable upon the exercise of this Agreement in compliance
with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish
to the Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance
with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. The Company will
use commercially reasonable efforts to maintain compliance with Rule 144 periodic reporting requirements.

 

(i)          Information
Rights. In the event the Company ceases to file reports pursuant to the 1934 Exchange Act (as defined below), Warrantholder
shall be entitled to the information rights contained in Section 7.1 of the Loan Agreement, and Section 7.1 of the Loan Agreement
is hereby incorporated into this Agreement by this reference as though fully set forth herein, provided, however, that the Company
shall not be required to deliver a Compliance Certificate once all Indebtedness (as defined in the Loan Agreement) owed by the
Company to Warrantholder has been repaid.

 

SECTION 10.     REPRESENTATIONS
AND COVENANTS OF THE WARRANTHOLDER.

 

This Agreement has been entered into by the Company in reliance
upon the following representations and covenants of the Warrantholder:

 

(a)          Investment
Purpose. This Warrant and the right to acquire the Common Stock are being acquired for investment and not with a view to the
sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution
of such rights or the Common Stock except pursuant to an effective registration statement or an exemption from the registration
requirements of the Act.

 

(b)          Private
Issue. The Warrantholder understands (i) that the Warrant and the Common Stock issuable upon exercise of this Agreement are
not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by
this Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s
reliance on such exemption is predicated on the representations set forth in this Section 10.

 

(c)          Financial
Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of its investment, and has the ability to bear the economic risks of its investment.

 

(d)          Risk
of No Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12
of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934
Act, or if a registration statement covering the securities under the Act is not in effect when it desires to sell (i) the rights
to purchase Common Stock pursuant to this Agreement or (ii) the Common Stock issuable upon exercise of the right to purchase, it
may be required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its
rights hereunder to purchase Common Stock or (B) Common Stock issued or issuable hereunder which might be made by it in reliance
upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule.

 

    	7

    	 

    

 

(e)          Accredited
Investor. Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule 501
of Regulation D, as presently in effect.

 

SECTION 11.     TRANSFERS.

 

Subject to compliance with applicable federal and state securities
laws, this Agreement and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except
for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding
the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof,
when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the
Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled
to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company
upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”),
at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer.
Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes.

 

SECTION 12.     MISCELLANEOUS.

 

(a)          Effective
Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed
and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company.

 

(b)          Remedies.
In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in
equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action
for specific performance for any default where Warrantholder will not have an adequate remedy at law and where damages will not
be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the Warrantholder or any other
person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining the
Company from continuing to commit any such breach of this Agreement.

 

(c)          No
Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid
the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying
out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of
the Warrantholder against impairment.

 

(d)          Additional
Documents. The Company, upon execution of this Agreement, shall provide the Warrantholder with certified resolutions with respect
to the representations, warranties and covenants set forth in Sections 9(a) through 9(d), 9(f) and 9(g). The Company shall also
supply such other documents as the Warrantholder may from time to time reasonably request.

 

(e)          Attorney’s
Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing
party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement.
For the purposes of this Section 12(e), attorneys’ fees shall include without limitation fees incurred in connection with
the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection
with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and
proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment.

 

(f)          Severability.
In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable,
the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced
by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying
the invalid, illegal or unenforceable provision.

 

    	8

    	 

    

 

(g)          Notices.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication
that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing,
and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission
by facsimile or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the
recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter,
or the first business day after deposit with an overnight express service or overnight mail delivery service; or (ii) the
third calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to
the party to be notified as follows:

 

If to Warrantholder:

Hercules Technology
III, L.P.

Legal Department

Attention: Chief Legal Officer and Manuel Henriquez

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

Facsimile: 650-473-9194

Telephone: 650-289-3060

 

If to the Company:

Neuralstem, Inc.

Attention: Richard Garr

9700 Great Seneca Parkway

Rockville, MD 20850

Facsimile: 301-560-6634

Telephone: 240-475-3148

 

or to such other address as each party may designate for itself
by like notice.

 

(h)          Entire
Agreement; Amendments. This Agreement constitute the entire agreement and understanding of the parties hereto in respect of
the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations
or other documents or agreements, whether written or oral, with respect to the subject matter hereof (including Lender’s
proposal letter dated February 22, 2013). None of the terms of this Agreement may be amended except by an instrument executed by
each of the parties hereto.

 

(i)          Headings.
The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of
this Agreement or any provisions hereof.

 

(j)          Advice
of Counsel. Each of the parties represents to each other party hereto that it has discussed (or had an opportunity to discuss)
with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p). 12(q) and 12(r).

 

(k)          No
Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement.

 

(l)          No
Waiver. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance
of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right
or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions
thereafter.

 

    	9

    	 

    

 

(m)          Survival.
All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto shall be
for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination
of this Agreement.

 

(n)          Governing
Law. This Agreement has been negotiated and delivered to Warrantholder in the State of California, and shall have been accepted
by Warrantholder in the State of California. Delivery of Common Stock to Warrantholder by the Company under this Agreement is due
in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the
State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

 

(o)          Consent
to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement,
each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, State of California;
(b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense
based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered
thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this
Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall be deemed
effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner
permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

 

(p)          Mutual
Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically
resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration
rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER
SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY
CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR
BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons
other than Borrower and Lender; Claims that arise out of or are in any way connected to the relationship between the Company and
Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind,
arising out of this Agreement.

 

(q)          Judicial
Reference. If the waiver of jury trial set forth above is ineffective or unenforceable, the parties agree that all Claims shall
be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually
acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of Santa Clara County, California.
Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable
to such proceeding.

 

(r)          Prejudgment
Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent jurisdiction
identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief
enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial
reference.

 

(s)          Counterparts.
This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by
different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which
counterparts shall constitute but one and the same instrument.

 

    	10

    	 

    

 

(t)          Specific
Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to Warrantholder
by reason of the Company’s failure to perform any of the obligations under this Agreement and agree that the terms of this
Agreement shall be specifically enforceable by Warrantholder. If Warrantholder institutes any action or proceeding to specifically
enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense
therein that Warrantholder has an adequate remedy at law, and such person shall not offer in any such action or proceeding the
claim or defense that such remedy at law exists.

 

[Remainder of Page Intentionally Left Blank]

 

    	11

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed by its officers thereunto duly authorized as of the Effective Date.

 

	COMPANY:	NEURALSTEM, INC.
	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 
	 	 
	WARRANTHOLDER:	HERCULES TECHNOLOGY III, L.P.,
	 	a Delaware limited partnership
	 	 	 
	 	By:	Hercules Technology SBIC Management, LLC,
	 	 	its General Partner
	 	 	 
	 	By:	Hercules Technology Growth Capital, Inc.,
	 	 	its Manager
	 	 	 
	 	By:	 
	 	Name: 	Benjamin Bang
	 	Title:	Senior Counsel

 

    	12

    	 

    

 

EXHIBIT I

 

NOTICE OF EXERCISE

 

		To:	NEURALSTEM, INC.

 

		(1)	The undersigned Warrantholder hereby elects to purchase
[_______] shares of the Common Stock of Neuralstem, Inc., pursuant to the terms of the Agreement dated the 22nd day of March,
2013 (the “Agreement”) between Neuralstem, Inc. and the Warrantholder, and [CASH PAYMENT: tenders herewith payment
of the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a)
of the Agreement to effect a Net Issuance.]

 

		(2)	Please issue a certificate or certificates representing
said shares of Common Stock in the name of the undersigned or in such other name as is specified below.

 

	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)
	 	 
	WARRANTHOLDER:	HERCULES TECHNOLOGY III, L.P.,
	 	a Delaware limited partnership
	 	 	 
	 	By:	Hercules Technology SBIC Management, LLC,
	 	 	its General Partner
	 	 	 
	 	By:	Hercules Technology Growth Capital, Inc.,
	 	 	its Manager
	 	 	 
	 	By:	 
	 	Name: 	 
	 	Title:	 
	 	Date:	 

 

    	13

    	 

    

 

EXHIBIT II

 

ACKNOWLEDGMENT OF EXERCISE

 

The undersigned Neuralstem, Inc., hereby acknowledge receipt
of the “Notice of Exercise” from Hercules Technology III, L.P. to purchase [____] shares of the Common Stock of Neuralstem,
Inc., pursuant to the terms of the Agreement, and further acknowledges that [______] shares remain subject to purchase under the
terms of the Agreement.

 

	 	COMPANY:	NEURALSTEM, INC.
	 	 	 	 
	 	 	By:	 
	 	 	 	 
	 	 	Title:	 
	 	 	 	 
	 	 	Date:	 

 

    	14

    	 

    

 

EXHIBIT III

 

TRANSFER NOTICE

 

(To transfer or assign the foregoing Agreement, execute this
form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced
thereby are hereby transferred and assigned to

 

	 	 	 
	(Please Print)	 	 
	 	 	 
	whose address is 	 	 
	 	 	 
	 	 	 

 

 

	 	Dated:	 

 

	 	Holder’s Signature:	 
	 	 	 
	 	Holder’s Address:	 
	 	 
	 	 

 

 

	Signature Guaranteed: 	 	 

 

NOTE:  The signature to this Transfer Notice must
correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any change whatever.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority
to assign the foregoing Agreement.

 

    	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]